Opinion: America's Biotech Race with China Must Be Won at Home

Former Commerce Secretary Gary Locke and Congressman Patrick McHenry argue that the United States must strengthen its domestic biotech capabilities to maintain its competitive edge against China. The opinion piece emphasizes that investing in homegrown research, development, and innovation infrastructure is essential for American leadership in biotechnology. This focus on domestic biotech advancement has significant implications for the future of pharmaceutical development, medical treatments, and healthcare solutions available to patients. By prioritizing internal capabilities, the U.S. aims to accelerate the development of breakthrough treatments for various diseases and conditions affecting millions of Americans.